Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much ...

A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Top-line results from the TRIUMPH-4 trial, carried out in patients with overweight or obesity and knee osteoarthritis, raise expectations for the prospects of retatrutide, which targets GLP-1, GIP, ...

Some of the world’s biggest technology companies slumped concerns over Oracle Corp.’s plans for vast capital outlays on ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

Novo Nordisk A/S (NYSE:NVO) is one of the Cheap NYSE Stocks to Buy Now. On December 5, Reuters reported that Novo Nordisk A/S ...